Short Course 1: Approaches for Developing Novel Digital Endpoints for Medical Product Development
Jennifer Goldsack, MA, MBA, MS
- Executive Director
- Digital Medicine Society (DiMe), United States
Jen Goldsack is the executive director of the Digital Medicine Society (DiMe). Founded in 2019, DiMe is the first professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. DiMe is a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. We do this by serving professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices.
Lindsay Stiles Kehoe, MS
- Project Manager
- Clinical Trials Transformation Initiative (CTTI), United States
Lindsay Kehoe is a project manager at the Clinical Trials Transformation Initiative (CTTI), currently managing the implementation of CTTI's digital Novel Endpoints project. Prior to joining CTTI, she coordinated genetic and rare disease clinical trials at Children’s National Medical Center and served on the hospital's Institutional Review Board. Early in her career, Ms. Kehoe worked in early phase drug development at Millennium Pharmaceuticals (now Takeda Oncology) and then post-marketing laboratory surveillance at Sanofi Genzyme. She has a genetic counseling degree from Boston University School of Medicine and a genetic counseling fellowship at the University of Virginia.
Michelle Crouthamel, PhD
- Director of Digital Health and Innovation
- AbbVie, Inc., United States
Michelle Crouthamel is a recognized industry leader who integrates digital health in pharmaceutical development and collaborates broadly with academics, tech, consortia, and health authorities to create impact. As the Director of Digital Health & Innovation at AbbVie, Michelle leads digital strategy and implementation. Prior to joining AbbVie, Michelle led many successful R&D programs at Merck and GSK. She is a scientific advisor to many tech companies, an inventor who holds multiple patents, and an author who published extensively in Neuroscience, Oncology, and Digital Health. Michelle has a Doctorate degree from the Fox Business School, Temple University and a Master's degree from the Institute of Neuroscience, Yang-Ming University, ROC.